坦维克斯生物制药公司的生物类似药NYPOZITM用于化疗诱导的中性质减退,获得FDA批准. Tanvex BioPharma's biosimilar NYPOZI™ for chemotherapy-induced neutropenia receives FDA approval.

美国Tavex BioPharma公司的生物类似药NYPOZITM (filgrastim- txid) 已获得FDA批准用于治疗癌症患者的化疗诱导的中性质减退症. Tanvex BioPharma USA's biosimilar NYPOZI™ (filgrastim-txid) was FDA-approved for treating chemotherapy-induced neutropenia in cancer patients. 这是在FDA批准Tanvex的BLA用于TX-05之后的,这是一种针对HER2阳性乳腺癌和胃癌的抗瘤生物药物. This follows the FDA's acceptance of Tanvex's BLA for TX-05, an antineoplastic biologic targeting HER2-positive breast and gastric cancer. 这证明了Tanvex在生物仿制药和合同生物制药开发和制造方面的专业知识, This validates Tanvex's expertise in biosimilars and contract biologics development & manufacturing, utilizing their FDA-licensed facility.